Interviews

Interview with Yannick Devaud, CEO of KOVE Medical on Amniosnare: Advancing Safer Fetal Surgery

KOVE Medical – Advancing Innovation in Fetal Surgery

KOVE Medical is developing Amniosnare, an innovative medical device designed to address one of the major challenges in fetal surgery: closing the amniotic sac after minimally invasive procedures.

Fetal surgery offers the possibility of treating certain congenital conditions before birth. However, the small opening created in the amniotic membrane during these interventions cannot currently be reliably closed, increasing the risk of membrane rupture, amniotic fluid leakage and premature birth.

Amniosnare aims to overcome this limitation through a minimally invasive suturing device that operates through an access port of approximately 3.6 mm. With over €1.2 million in Innosuisse funding, KOVE Medical is advancing its technology towards clinical validation and regulatory approval.

We spoke with Yannick Devaud, CEO of KOVE Medical, to explore the origins of Amniosnare, the technical challenges behind its development, the results of its preclinical studies and how Innosuisse funding is supporting the company’s journey towards bringing safer fetal surgery to patients.

See the Success Story

1. Yannick, KOVE grew out of your research at the University of Zurich. When did you realise that closing the amniotic sac after fetal surgery was a problem worth building a company around?

Even before starting my PhD, I wanted to work on a project linked to a clinical application. I didn’t want to focus solely on basic scientific research, but on developing something that could be applied in practice.

That’s how I got involved with the hospital, where they introduced us to the problems they were facing in fetal therapy. I thought my research could help develop a practical solution to one of these problems. From the beginning, I chose my PhD project with the intention of developing something that could be applied.

During my research, I got in touch with many people in the fetal therapy community and realised that this was a problem everybody was facing.

Reading papers in the field, I saw that the lack of a solution to close the amniotic sac was a recurring challenge. There was a shared view that finding a solution could unlock the potential of fetoscopy.

It was through these interactions and the feedback I received from the community that I recognised the potential of the project. The problem had been reported for years, and there was agreement that something needed to be done.

2. Amniosnare has to work through a port of just 3.6 mm inside a pregnant uterus. What has been the biggest technical challenge in designing a device for such a delicate environment?

The biggest challenge has definitely been the size. We’re working with an access port of approximately 3.5 to 3.6 millimetres in diameter, which means everything has to fit and function within a very limited space.

At that scale, we’re approaching the physical limits of what is mechanically possible in terms of bending, pushing and pulling. Moving from a larger initial concept to a device small enough to work through such a narrow port required several years of development and significant investment. It was a nightmare at times!

3. Your preclinical studies achieved successful closure in 91% of cases. What did these results teach you, and what are you most looking forward to learning from the first-in-human study?

First, I’d like to clarify an important distinction in the results. We achieved successful closure of the defect in 91% of cases, but 100% of the successfully stitched defects were watertight.

In the study, we had two unsuccessful closures out of 22 cases. These cases helped us identify certain limitations, understand what went wrong and introduce risk mitigation measures into the process and production.

The next step is to understand how the human uterus behaves compared to the sheep uteruses used in our studies.

Our preclinical studies were conducted using sheep uteruses. Although we’ve developed silicone models that replicate the properties of real tissue as closely as possible, we still don’t know how human tissue will react in a real clinical setting.

We’re also looking forward to performing the procedure using only ultrasound visibility rather than full camera vision.

4. Beyond preventing preterm birth, how do you think Amniosnare could change fetal surgery for surgeons, hospitals and families?

Our main indication is the closure of defects in the amniotic sac. We’re repairing these openings, and the ultimate long-term goal is to demonstrate that this can prevent premature birth or rupture of the membranes. This could have a big impact because it would allow surgeons to perform surgeries for other indications where the risk-reward ratio is currently too high.

If we can reduce those risks, surgeons may be able to offer fetal interventions for a wider range of conditions. They may also be able to perform certain procedures earlier in pregnancy, which has been shown to improve outcomes in some cases.

Ultimately, we hope this technology will allow surgeons to treat more babies, intervene earlier when appropriate and achieve better outcomes for both babies and their families.

5. With over €1.2 million secured from Innosuisse, what are the most important milestones ahead on the way to market approval in the US and Europe?

We have several important milestones ahead. The first milestone is conducting another preclinical study in sheep, this time following Good Laboratory Practice (GLP) standards. Having GLP-compliant preclinical data is important for US Food and Drug Administration (FDA) approval.

We’ll also conduct a first-in-human study in Brazil, where one of the leading centres is ready. We’ve been collaborating with the centre for approximately a year to develop the study protocol, so this is a major milestone for us. This will be an important step in evaluating the technology in a clinical setting.

Another important milestone is conducting a safety study in the United States as part of our regulatory pathway.

We have obtained a Humanitarian Use Device (HUD) designation, and we’re pursuing the Humanitarian Device Exemption (HDE) pathway. The safety study will be an important part of generating the evidence needed for regulatory review.

The final milestone will be submitting all the necessary data to the FDA to seek approval to bring the device to the US market.

6. How was your experience working with Evolution Europe during the Innosuisse application process, and what value did our team bring to the project?

Our experience working with Evolution Europe was very positive. This isn’t the first successful grant we’ve secured through our collaboration. It was particularly great working with Maria. She was very hands-on, and I appreciated having someone who genuinely understood our project.

The team made a real effort to understand the technology and its objectives. They didn’t simply help us write the application; they brought an outside perspective, contributed ideas and helped us identify which aspects of the project were most important to highlight.

They also raised strategic questions that encouraged us to think more critically about certain elements of our project, which was valuable. Another aspect I appreciated was how well-organised the process was. It was always clear what needed to be done and what we had to review.

Between meetings, the team made a lot of progress, so we only needed to review the modifications rather than go through everything again. The team kept track of everything that needed to be done, maintained a clear plan and worked alongside us throughout the process.

 

KOVE Medical – Innosuisse SIP Success Story

Kove Team – Kurt Ruffieux, CTO and Yannick Devaud, CEO


Ready to secure your funding?

Let us help you unlock the full potential of your innovation. Whether you’re looking for grants,
private funding, or tax benefits, our experts are ready to guide you every step of the way.

Get your free consultation Contact us today